Baseline HIVDR mutations.

∧None of the participants with drug resistance at baseline were switched to alternative first-line or second-line treatment during the 12 month follow-up. The treatment shown was initiated after the baseline HIVDR genotyping.¥participant 1 showed baseline mutations, but was virologically suppressed at 12 months (see Table 4);*M184V/I cause high-level in vitro resistance to 3TC.**K103N and K103KN, A98AG and Y181CY cause high-level resistance to NVP and EFV. G190A causes high level resistance to NVP and intermediate resistance to EFV.The drugs in bold and underlined have a reduced sensitivity against the mutated viruses.Viral suppression is defined by VL≥1000copies/mL.